37 results about "Normal nerve conduction velocities" patented technology

Embodiments of the invention relate to a wireless physiological monitoring system. The system includes at least one wireless sensor and a monitoring device which are linked to one another of a wireless fashion for measuring physiological signals of a patient. The at least one wireless sensor is located on the patient and may comprise a wireless surface electrode assembly or a wireless needle assembly. The system may also comprise a wireless stimulator syncronized with the wireless sensor for performing certain diagnostic tests, such as nerve conduction velocity tests, for example. The wireless sensor preferably includes active, reference and common conductors. The common conductor can be used to measure the common mode voltage of the patient in the vicinity of the testing, and this voltage can then be subtracted from the measured active and reference voltages.

Embodiments of the invention relate to a wireless physiological monitoring system. The system includes at least one wireless sensor and a monitoring device which are linked to one another of a wireless fashion for measuring physiological signals of a patient. The at least one wireless sensor is located on the patient and may comprise a wireless surface electrode assembly or a wireless needle assembly. The system may also comprise a wireless stimulator synchronized with the wireless sensor for performing certain diagnostic tests, such as nerve conduction velocity tests, for example. The wireless sensor preferably includes active, reference and common conductors. The common conductor can be used to measure the common mode voltage of the patient in the vicinity of the testing, and this voltage can then be subtracted from the measured active and reference voltages.

The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to piperidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

The invention provides an application of a pyrroloquinoline quinone (PQQ) active substance in preparation of medicaments for treating and / or improving a diabetic complication, namely diabetic foot and further provides a health-care product composition or a pharmaceutical composition containing pyrroloquinoline quinone. The active substance, namely the pyrroloquinoline quinone in the composition provided by the invention has significant treatment and / improvement action against the diabetic complication, namely the diabetic foot by improving nerve conduction velocity, reducing sorbitol content, increasing the open number of capillaries, reducing whole blood viscosity, enhancing blood flow, increasing neural blood flow, promoting blood circulation, improving microcirculation of blood vessels and reducing gangrene ulcers of the foot. Therefore, the pyrroloquinoline quinone has great application prospects in prevention, treatment and / or improvement of occurrence and development of the diabetic complication, namely the diabetic foot.

The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

The invention provides a pharmaceutical composition for treating or preventing nerve damage. The pharmaceutical composition comprises the following components: asiaticoside, an Aloe vera extract, a sweetsop seed extract, a leontopodium alpinum extract, and a vascular endothelial growth factor (VEGF). The pharmaceutical composition of the invention is useful for inducing neurite outgrowth, for promoting stem cell function, and / or for promoting functional recovery and enhancing synapse formation and synaptic plasticity in damaged and / or injured neurons in acute and chronic injury, and can significantly alleviate impaired sciatic nerve function, increase nerve conduction velocity, increase axon count, and repair axons. Clinical studies show that the pharmaceutical composition of the inventioncan improve muscle strength, accelerate repair of damaged nerve tissue, and improve nerve tissue transmission and metabolic disorders in patients with peripheral nerve injury.

The present invention relates to heterocyclic compounds useful for antagonizing angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to piperazine and diazepine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

The present invention provides methods and compositions for the effective treatment of impaired nerve signal conduction. Compositions including selective AT2 receptor antagonists as active agents and methods of use in relation to improving nerve signal conduction or reversing impaired nerve signal conduction are described.

The invention relates to a medicinal composition for treating the diabetic peripheral neuropathy, and a preparation method thereof. The medicinal composition is mainly composed of Radix Astragali, Ligustri Lucidi Fructus, cassia twig, Radix Paeoniae Rubra, Radix Scutellariae, Rhizoma Coptidis, leech and the like, and the medicinal composition can be processed through using pharmaceutically acceptable carriers or excipients to prepare medicaments comprising a capsule, a granule, a tablet, a soft capsule, a pill and the like. The medicinal composition has the qi tonifying, yin nourishing, detoxifying, blood stasis dispersing and vein relaxing efficacies, and can be taken by diabetic peripheral neuropathy patients. Clinic research results show that the medicinal composition can obviously improve limb numbness, limb aches, lime end coldness, abnormal sensation, fatigue, asthenia and the like of the diabetic peripheral neuropathy patients, obviously improves the nerve conduction velocity and the terminal microcirculation, substantially reduces the content of sorbitol in erythrocytes, and has no obviously untoward effects.

The invention belongs to the technical field of a traditional Chinese medicine, and particularly relates to a medicine for treating diabetic peripheral neuropathy, a preparation method thereof and usethereof. The medicine for treating diabetic peripheral neuropathy is obtained by combining a mixed extract of a cassia seed water extract and a cassia ethanol extract with an extraction part containing an anthraquinone compound, unsaturated fatty acid, and a naphthoppyrone component. The medicine can improve peripheral nerves by increasing nerve conduction velocity and improving local microcirculation, and thus can play a role in preventing and treating the diabetic peripheral neuropathy.

The invention discloses a Chinese medicinal extract for treating diabetic peripheral neuropathy and a preparation method thereof. The Chinese medicinal extract is extracted from the following seven traditional Chinese medicines serving as raw materials in parts by mass: 600-1,200 parts of astragalus root, 600-1,200 parts of salvia miltiorrhizae, 400-600 parts of rhizoma cibotii, 400-600 parts of root of bidentate achyranthes, 400-600 parts of pawpaw, 400-600 parts of corydalis tuber and 400-600 parts of red paeony root. Clinical test results show that clinical symptoms of a patient of diabetic peripheral neuropathy can be obviously improved and nerve conduction velocity of the DPN patient can be effectively increased by the Chinese medicinal extract, and the overall effectiveness ratio reaches 90.3 percent; meanwhile, the improvement in the aspects of numbness, seismesthesia, spasm, touch sensation, pain, pinprick sensation and ankle reflection is also superior to that of a control group. The overall curative effect evaluation is obviously superior to that of a vitamin preparation, namely methycobal (P is less than 0.05), which is generally used in clinical practice at present. Blood routine and liver and kidney functions before and after treatment do not obviously differ; and during treatment, two groups of patients have no adverse effect. The compound granules are shown to be safe and effective for treating the diabetic peripheral neuropathy.

Disclosed is an agent for preventing and treating diabetic peripheral neuropathy including a granulocyte colony stimulating factor (G-CSF) as an active ingredient, which is able to improve nerve conduction velocity and pain sensitivity by regenerating blood vessels in peripheral tissues and rehabilitating damaged nerve tissues.

The present invention provides methods and compositions for the effective treatment of impaired nerve signal conduction. Compositions including selective AT2 receptor antagonists as active agents and methods of use in relation to improving nerve signal conduction or reversing impaired nerve signal conduction are described.

The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to compounds of formula (I), as described herein, compositions containing them and their CM use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

The invention discloses an application of a Zhenlong refreshing pharmaceutical composition in preparation of a medicine for treating diabetic peripheral neuropathy. A Zhenlong refreshing preparation is traditionally used for treating acute cerebral infarction, carotid atherosclerosis plaque, apoplexy sequela, etc. Pharmacological experiments and clinical observations prove that the Zhenlong refreshing pharmaceutical composition disclosed by the invention comprises a Zhenlong refreshing capsule and a Zhenlong refreshing pharmaceutical composition prepared by an improved process, the Zhenlong refreshing pharmaceutical composition obviously perfects the symptoms of a nervous system of a DNP (diabetic peripheral neuropathy) patient and can significantly improve the nerve conduction velocity and perfect a variety of biochemical indexes, so that the Zhenlong refreshing pharmaceutical composition can be used for treating and preventing DPN.

An implantable device, or an associated computer program, for estimating a nerve conduction velocity. A stimulus is applied from one or more stimulus electrodes to a nerve. A digitised neural measurement of at least one compound action potential evoked by the at least one stimulus is obtained from one or more recording electrodes by measurement circuitry. The digitised neural measurement comprises a plurality of data sample points. The digitised neural measurement is processed in order to estimate within subsample precision a temporal position of a feature of interest of the compound action potential. From the estimated temporal position of the feature of interest, and from a propagation distance, a conduction velocity of the compound action potential is determined.

The invention discloses a four stem powder traditional Chinese medicine composition for treating diabetic foot. The four stem powder traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 13-27 parts of radix clematidis, 22-35 parts of uncaria rhynchophylla, 22-35 parts of caulis spatholobi, 22-35 parts of Chinese starjasmine stem, 22-35 parts of kadsura pepper stem, 10-20 parts of semen brassicae, 22-35 parts of cassia twig, 22-35 parts of garden balsam stem, 10-20 parts of sanguisuga, 10-20 parts of peach kernel, 10-20 parts of safflower, 13-27 parts of lumbricus, 22-35 parts of herba siegesbeckiae, 13-27 parts of lycopodium clavatum, 22-35 parts of medicinal cyathula roots and 13-27 parts of rhizoma acori graminei. The raw materials in a formula have functions of removing blood stasis, invigorating the circulation of blood, eliminating turbid and dredging collaterals, and have good curative effect on the diabetic foot together with application of lipoic acid; the total effective rate is 87.4 percent; the clinical symptoms and the nerve conduction velocity are relieved, and the treatment course is shortened.

The invention provides an application of a TNF (tumor necrosis factor)-alpha receptor-antibody fusion protein, including application of TNF-alpha receptor-antibody fusion protein in preparation of medicaments for treating diabetic peripheral neuropathy (DPN), delaying diabetic peripheral neuropathy and increasing nerve conduction velocity or relieving nerve demyelination. The application provided by the invention has the advantages that the TNF-alpha receptor-antibody fusion protein is applied to a DPN rat model to inhibit the function of TNF-alpha, and the influences of the TNF-alpha receptor-antibody fusion protein on the nerve conduction velocity of a DPN rat, nervous tissue pathological alteration and myelin basic protein expression are observed, so that the action of the TNF-alpha in the pathogenesis of the DPN is made clear, and the effects of the TNF-alpha receptor-antibody fusion protein in delaying the development of peripheral neuropathy of the DPN rat, improving the expression of sciatic nerve morphology of the DPN rat and relieving demyelination of sciatic nerve are proved. Thus, the TNF-alpha receptor-antibody fusion protein has a wide application prospect in the preparation of medicaments for treating diabetic peripheral neuropathy.

The invention provides an application of a TNF (tumor necrosis factor)-alpha receptor-antibody fusion protein, including application of TNF-alpha receptor-antibody fusion protein in preparation of medicaments for treating diabetic peripheral neuropathy (DPN), delaying diabetic peripheral neuropathy and increasing nerve conduction velocity or relieving nerve demyelination. The application provided by the invention has the advantages that the TNF-alpha receptor-antibody fusion protein is applied to a DPN rat model to inhibit the function of TNF-alpha, and the influences of the TNF-alpha receptor-antibody fusion protein on the nerve conduction velocity of a DPN rat, nervous tissue pathological alteration and myelin basic protein expression are observed, so that the action of the TNF-alpha in the pathogenesis of the DPN is made clear, and the effects of the TNF-alpha receptor-antibody fusion protein in delaying the development of peripheral neuropathy of the DPN rat, improving the expression of sciatic nerve morphology of the DPN rat and relieving demyelination of sciatic nerve are proved. Thus, the TNF-alpha receptor-antibody fusion protein has a wide application prospect in the preparation of medicaments for treating diabetic peripheral neuropathy.

The invention relates to a concrete application of bone marrow mesenchymal stem cells-derived neuron cells (mNCs), solves a problem that no medicines for specially effectively treating n-hexane induced peripheral neuropathy traditionally exist, and provides a new idea for treating the neuropathy and the concrete application of the neuron cells. Results of experiments with rats suffering from the n-hexane induced peripheral neuropathy as an experiment object and gait score, nerve electrophysiology (nerve conduction latency and nerve conduction velocity), and solochrome cyanine staining, scanning electron microscope, myelin basic proteins and low molecular weight neurofilaments of spinal marrow and sciatic nerves as detection indexes show that the mNCs has a substantial restoration effect on the rats suffering from the n-hexane induced peripheral neuropathy as the medicine for treating n-hexane induced peripheral neuropathy, and has important effects in the treatment of occupational poisoning induced peripheral neuropathy.

Disclosed is an agent for preventing and treating diabetic peripheral neuropathy including a granulocyte colony stimulating factor (G-CSF) as an active ingredient, which is able to improve nerve conduction velocity and pain sensitivity by regenerating blood vessels in peripheral tissues and rehabilitating damaged nerve tissues.

Disclosed herein are an agent for treating traumatic peripheral nerve injury comprising a granulocyte colony stimulating factor (G-CSF) as an active ingredient and a method for treating traumatic peripheral nerve injury with the same.The therapeutic agent advantageously regenerates nerve cells and blood vessels in peripheral nerve tissues and thus rehabilitates the injured nerve tissues to improve nerve conduction velocity, and relieves pain induced by traumatic peripheral nerve injury.

The invention discloses a four stem powder traditional Chinese medicine composition for treating diabetic foot. The four stem powder traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 13-27 parts of radix clematidis, 22-35 parts of uncaria rhynchophylla, 22-35 parts of caulis spatholobi, 22-35 parts of Chinese starjasmine stem, 22-35 parts of kadsura pepper stem, 10-20 parts of semen brassicae, 22-35 parts of cassia twig, 22-35 parts of garden balsam stem, 10-20 parts of sanguisuga, 10-20 parts of peach kernel, 10-20 parts of safflower, 13-27 parts of lumbricus, 22-35 parts of herba siegesbeckiae, 13-27 parts of lycopodium clavatum, 22-35 parts of medicinal cyathula roots and 13-27 parts of rhizoma acori graminei. The raw materials in a formula have functions of removing blood stasis, invigorating the circulation of blood, eliminating turbid and dredging collaterals, and have good curative effect on the diabetic foot together with application of lipoic acid; the total effective rate is 87.4 percent; the clinical symptoms and the nerve conduction velocity are relieved, and the treatment course is shortened.

The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to compounds of formula (I), as described herein, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

The present invention relates to heterocyclic compounds useful for antagonizing angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to piperidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

The present invention relates to application of drofenine or a pharmaceutically acceptable salt thereof in the preparation of medicine for treating peripheral neuron axonal injury and peripheral related neuropathy. The drofenine or the pharmaceutically acceptable salt thereof has a significant effect on promoting growth of peripheral sensory neurites, and can relieve symptoms of low nerve conduction velocity and sensation loss of STZ-induced type I diabetic mice and db / db type II diabetic mice, thereby treating diabetic peripheral neuropathy.

Disclosed herein are an agent for treating traumatic peripheral nerve injury comprising a granulocyte colony stimulating factor (G-CSF) as an active ingredient and a method for treating traumatic peripheral nerve injury with the same.The therapeutic agent advantageously regenerates nerve cells and blood vessels in peripheral nerve tissues and thus rehabilitates the injured nerve tissues to improve nerve conduction velocity, and relieves pain induced by traumatic peripheral nerve injury.

The invention discloses a traditional Chinese medicine composition used for treating peripheral nerve injury. The traditional Chinese medicine composition used for treating peripheral nerve injury isprepared from the following raw materials: prepared radix rehmanniae, caulis spatholobi, radix rhodiolae, pilose antler, ganoderma lucidum, Chinese starjasmine stem, and common heron's bill herb. Thetraditional Chinese medicine composition provided by the invention has the functions of benefiting Qi, tonifying the blood, reducing phlegm and dredging collateral; and thus, the traditional Chinese medicine composition is suitable for treating the symptoms of muscle and tendon atrophy, loss of skin perception and numbness caused by peripheral nerve injury. The traditional Chinese medicine composition provided by the invention is capable of significantly improving function of damaged sciatic nerve, accelerating nerve conduction velocity, increasing neuroaxon count and restoring nerve axons. Being used for treating patients with peripheral nerve injury, the traditional Chinese medicine composition provided by the invention is capable of enhancing muscle strength, accelerating repair of injured nerve tissues, as well as improving neurotransmission and metabolic disorders.